Joseph A Fraietta

faculty photo
Adjunct Assistant Professor of Pathology and Laboratory Medicine
Associate Director, Product Development , Center for Advanced Cellular Therapeutics University of Pennsylvania
Department: Pathology and Laboratory Medicine

Contact information
Center for Advanced Cellular Therapeutics
Perelman Center for Advanced Medicine South Tower (ST9)
University of Pennsylvania
3400 Civic Center Boulevard
Laboratory: 9-309 Office: 9-104
Philadelphia, PA 19104-5156
Office: 215-746-4083
Fax: 215-573-8590
Lab: 215-573-1880
Education:
Ph.D. (Microbiology and Immunology)
Drexel University College of Medicine, 2012.
Permanent link
 

Description of Itmat Expertise

1) Enhancing the specificity and efficacy of genetically-redirected T cells
2) Developing mechanisms to render T cells resistant to the tumor microenvironment
3) Improving the processes of engineering cells for infusion into patients
4) Interrogating the starting materials and cellular infusion products for key markers of potency

Description of Research Expertise

Our research focuses on developing cellular-based immunotherapy for the treatment of leukemia, lymphoma, myeloma, melanoma, glioblastoma, pancreatic cancer and other malignancies. Studies in the group are directed toward enhancing the specificity and efficacy of genetically-redirected T cells, developing mechanisms to render T cells resistant to the immunosuppressive tumor microenvironment and improving the processes of engineering cells for infusion into patients. We also interrogate cellular products for key markers of potency using biochemical, molecular as well as cell-based assays. Our long-term goals include the 1) development of novel methodologies using adoptive T cell-directed approaches, to enhance patient immunity against cancer and 2) generation of comprehensive, quality-driven platforms to predict as well as evaluate the impact of experimental treatments on patient biology/the disease to allow for a rational and data-driven iterative cycle of translational research. As part of the Center for Advanced Cellular Therapeutics, we closely interact with other scientists, clinicians, study coordinators and an active clinical trials research program to translate laboratory insights into safe and effective cancer treatments.

Selected Publications

Lorena Loarca*, Joseph A. Fraietta*, Vanessa Pirrone, Zsofia Szep and Brian Wigdahl *Co-first author : Human Immunodeficiency Virus (HIV) Infection and Cancer. HIV/AIDS - Contemporary Challenges. Nancy Dumais (eds.). InTech, Page: 3-42, Feb 2017

Long Meixiao, Beckwith Kyle, Do Priscilla, Mundy Bethany L, Gordon Amber, Lehman Amy M, Maddocks Kami J, Cheney Carolyn, Jones Jeffrey A, Flynn Joseph M, Andritsos Leslie A, Awan Farrukh, Fraietta Joseph A, June Carl H, Maus Marcela V, Woyach Jennifer A, Caligiuri Michael A, Johnson Amy J, Muthusamy Natarajan, Byrd John C: Ibrutinib treatment improves T cell number and function in CLL patients. The Journal of clinical investigation 127(8): 3052-3064, Aug 2017.

Joseph A. Fraietta, J. Joseph Melenhorst, Bruce L. Levine: Cell intrinsic PD-1 checkpoint blockade releases the brake on human chimeric antigen receptor (CAR) T cells for solid tumors. Translational cancer research 5(7): S1328-S1332, December 2016.

Ruella Marco, Kenderian Saad S, Shestova Olga, Fraietta Joseph A, Qayyum Sohail, Zhang Qian, Maus Marcela V, Liu Xiaobin, Nunez-Cruz Selene, Klichinsky Michael, Kawalekar Omkar U, Milone Michael, Lacey Simon F, Mato Anthony, Schuster Stephen J, Kalos Michael, June Carl H, Gill Saar, Wasik Mariusz A: The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma. Clinical cancer research 22(11): 2684-96, Jun 2016.

Fraietta Joseph A, Schwab Robert D, Maus Marcela V: Improving therapy of chronic lymphocytic leukemia with chimeric antigen receptor T cells. Seminars in oncology 43(2): 291-9, Apr 2016.

Long Kristen B, Gladney Whitney L, Tooker Graham M, Graham Kathleen, Fraietta Joseph A, Beatty Gregory L: IFNγ and CCL2 Cooperate to Redirect Tumor-Infiltrating Monocytes to Degrade Fibrosis and Enhance Chemotherapy Efficacy in Pancreatic Carcinoma. Cancer discovery 6(4): 400-413, Apr 2016.

Carey Alison J, Gracias Donald T, Thayer Jillian L, Boesteanu Alina C, Kumova Ogan K, Mueller Yvonne M, Hope Jennifer L, Fraietta Joseph A, van Zessen David B H, Katsikis Peter D: Rapid Evolution of the CD8+ TCR Repertoire in Neonatal Mice. Journal of immunology 196(6): 2602-13, Mar 2016.

Fraietta Joseph A, Beckwith Kyle A, Patel Prachi R, Ruella Marco, Zheng Zhaohui, Barrett David M, Lacey Simon F, Melenhorst Jan Joseph, McGettigan Shannon E, Cook Danielle R, Zhang Changfeng, Xu Jun, Do Priscilla, Hulitt Jessica, Kudchodkar Sagar B, Cogdill Alexandria P, Gill Saar, Porter David L, Woyach Jennifer A, Long Meixiao, Johnson Amy J, Maddocks Kami, Muthusamy Natarajan, Levine Bruce L, June Carl H, Byrd John C, Maus Marcela V: Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood 127(9): 1117-27, Mar 2016.

Kawalekar Omkar U, O'Connor Roddy S, Fraietta Joseph A, Guo Lili, McGettigan Shannon E, Posey Avery D, Patel Prachi R, Guedan Sonia, Scholler John, Keith Brian, Snyder Nathaniel W, Snyder Nathaniel, Blair Ian A, Blair Ian, Milone Michael C, June Carl H: Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells. Immunity 44(2): 380-90, Feb 2016.

Gracias Donald T, Boesteanu Alina C, Fraietta Joseph A, Hope Jennifer L, Carey Alison J, Mueller Yvonne M, Kawalekar Omkar U, Fike Adam J, June Carl H, Katsikis Peter D: Phosphatidylinositol 3-Kinase p110δ Isoform Regulates CD8+ T Cell Responses during Acute Viral and Intracellular Bacterial Infections. Journal of immunology 196(3): 1186-98, Feb 2016.

back to top
Last updated: 09/26/2017
The Trustees of the University of Pennsylvania